The formation of new life sciences-focused venture firms is rare, even in strong markets. But biotech researchers and entrepreneurs can now add another notable name as a potential source of capital.
Cure Ventures, a life sciences venture firm, today closed its debut $350 million fund. The Boston-based outfit was founded in 2021 by biopharma industry veterans Richard Lim, David Fallace and Lou Tartaglia, who have prior experience in top VC firms such as Third Rock Ventures and Polaris, as well as major roles in breakout biotech companies, including Juno Therapeutics and Nuvation Bio.
So far in 2023, biotech and pharmaceutical companies have raised $4.1 billion across 208 VC deals, according to PitchBook data. That’s a far cry—on an annualized basis—from the deal activity the industry saw in the previous five years.
Lim believes that the slowing of deal activity is not only normal but also healthy because investors are not bidding up valuations anymore.
“Science continues to plod along,” said Lim, who was a managing director at Omega Funds, a healthcare-focused PE firm, for more than a decade. “It doesn’t do a hockey stick in terms of advancement.” He added that the industry is now getting back to a “proper” deal cadence.
The firm plans to write checks of up to several million dollars for about 20 seed-stage startups. Some of those companies will not work out, so the fund will ultimately have 12 to 15 companies in the portfolio, Lim said. The fund has already backed a handful of companies, but all remain in stealth mode.
Cure says that it is disease agnostic—it is backing companies developing drugs that treat cancer, neurological conditions and autoimmune disorders. The firm is investing in novel compounds as well as medicines that have already started clinical trials.
Strong science will always find investors, said Lim, who hopes to contribute to cures of many diseases.
“We chose quite an ambitious name for the firm,” he said. “We really didn’t want to be viewed as ‘incremental’ ventures.”
Learn about our editorial standards.